Semaglutide provides double benefit for women with heart failure

FHS
June 24, 2024
5:08 pm

Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options.

Updated: In turnaround, ALX Oncology’s CD47 blocker shows efficacy in gastric cancer trial

Don’t write off CD47 just yet. ALX Oncology said that 52% of gastric cancer patients who received its anti-CD47 drug evorpacept in combination with a

October 4, 2023

Adding Immunotherapy to Neoadjuvant Chemo Boosts pCR in HR-Positive Breast Cancer

SAN ANTONIO — Adding an immune checkpoint inhibitor (ICI) to chemotherapy significantly increased the rate of pathologic complete response (pCR) and reduced residual cancer burden

December 8, 2023

Tableside bong service? A Denver weed lounge aims to reinvent nightlife – The Cannabist

When Denverite Arend Richard looks at the local and national landscape for cannabis lounges, he sees a homogenous smattering of spaces designed for men. That’s

May 3, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.